$2.050
-0.049 (-2.38%)Al cierre
- Máximo
- 2.190
- Apertura
- 2.150
- Precio medio ponderado por volumen
- 2.08
- Volumen
- 79.19K
- Capitalización
- 40.02M
- Mínimo
- 2.015
- Importe
- 165.10K
- EV/EBITDA, TTM
- 0.00
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations.
Métricas de valoración
Cronología de eventos
Noticias
3.003-14PRnewswireAadi Bioscience to Report Fourth Quarter and Full-Year 2024 Results and Corporate Update
8.503-04PRnewswireAadi Bioscience Announces Closing of $100 Million PIPE Financing
5.003-04NASDAQ.COMInsider Sale: CHIEF FINANCIAL OFFICER of $AADI Sells 2,806 Shares
8.503-03PRnewswireAadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders
1.002-24PRnewswireAadi Bioscience to Present at the TD Cowen 45th Annual Healthcare Conference
Preguntas frecuentes sobre AADI, respondidas por Alphio AI
Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. FYARRO is composed of nanoparticles of sirolimus bound to human albumin with an average size less than 100 nanometers. It has also initiated a tumor-agnostic Phase II study (PRECISION 1) of FYARRO in patients with Tuberous Sclerosis Complex 1 and 2 (TSC1 and TSC2) alterations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.